Pulmonx Corp

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

LUNG$2.800.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Revenue	$22,835	$21,502	$66,177	$67,899
Cost of goods sold	5,436	5,450	14,992	18,301
Gross profit	17,399	16,052	51,185	49,598
Operating expenses
Research and development	4,864	4,846	14,797	14,908
Selling, general and administrative	20,025	25,599	65,891	78,450
Total operating expenses	24,889	30,445	80,688	93,358
Loss from operations	(7,490)	(14,393)	(29,503)	(43,760)
Interest income	345	611	1,024	2,198
Interest expense	(1,234)	(805)	(3,428)	(2,385)
Other income, net	136	758	212	809
Net loss before tax	(8,243)	(13,829)	(31,695)	(43,138)
Income tax expense	151	128	433	440
Net loss	(8,394)	(13,957)	(32,128)	(43,578)
Other comprehensive (loss) income
Currency translation adjustment	(334)	(399)	(645)	147
Change in unrealized gains (losses) on marketable securities	—	1	—	(22)
Total other comprehensive (loss) income	(334)	(398)	(645)	125
Comprehensive loss	$(8,728)	$(14,355)	$(32,773)	$(43,453)
Net loss per share attributable to common stockholders, basic and diluted	$(0.19)	$(0.34)	$(0.76)	$(1.08)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	43,176,913	40,936,896	42,519,134	40,444,001

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.